Clinical trials: Coronavirus Sars-Associated
COVID, Covid-19
Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells
Treatment of patients with Covid-19 associated pneumonia using intravenous injection of allogenic pooled olfactory mucosa-derived mesenchymal stem cells
- Conditions
- COVID, Covid-19, Coronavirus, Pneumonia
- Trial name
- NCT04382547
- Testing
- Allogenic pooled olfactory mucosa-derived mesenchymal stem cells, Standard treatment according to the Clinical protocols
- Where
- Belarus
- Volunteers
- 32 people
- Sponsor
- Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
Covid19
TOCILIZUMAB - An Option for Patients With COVID-19 Associated Cytokine Release Syndrome; A Single Center Experience
Investigators conducted this study to see the effectiveness of Tocilizumab in COVID-19 participants who were in cytokine release syndrome and there was also a control group who received steroids(RECOVERY TRIAL wasn't published or…
- Trial name
- NCT04730323
- Testing
- Tocilizumab
- Where
- Pakistan
- Volunteers
- 93 people
- Sponsor
- FMH College of Medicine and Dentistry
COVID-19
Ozone Plasma on Lung Function and Inflammatory Parameters in Pulmonary Sequelae Associated With Coronavirus 19 Infection
The risk for the development of complications from COVID-19 occurs mainly in patients over 65 years of age, with obesity, arterial hypertension, chronic lung diseases and immunosuppression states.
- Trial name
- NCT05089305
- Testing
- Ozone plasma
- Where
- 2 sites in Mexico
- Volunteers
- 35 people
- Sponsor
- Centro Universitario de Ciencias de la Salud, Mexico
Paediatric Inflammatory Multisystem Syndrome-Temporally Associated With SARS-CoV-2 (PIMS-TS)
Randomised Evaluation of COVID-19 Therapy (RECOVERY) in Children With PIMS-TS in Switzerland (SWISSPED-RECOVERY)
The study is to provide reliable estimates of the effect of study treatment on hospital length of stay through to 28 days after randomisation.
- Trial name
- NCT04826588
- Testing
- Methylprednisolone sodium succinate 10 mg/kg intravenously, Human normal immunoglobulin (IVIg)
- Where
- 10 sites in Switzerland
- Volunteers
- 76 people
- Sponsor
- University Children's Hospital Basel
Covid19
Using Mixed-methods Approach to Explore the Long-term Effects of COVID-19
Researchers warned that up to 80% of the survivors may experience multiple and severe long-term symptoms, sometimes called Long Coronavirus Disease(Long COVID).
- Trial name
- NCT05303103
- Where
- Taiwan
- Volunteers
- 150 people
- Sponsor
- National Taiwan University Hospital
Covid19, SARS-CoV-2 PNEUMONIA
Safety and Efficiency of Method of Exosome Inhalation in COVID-19 Associated Pneumonia
Coronavirus is an acute viral disease with prevailing upper respiratory tract infections caused by the RNA-containing virus of the genus Betacoronavirus of the Coronaviridae family.
- Conditions
- Covid19, SARS-CoV-2 PNEUMONIA, COVID-19
- Trial name
- COVID-19EXO2 (NCT04602442)
- Testing
- EXO 1 inhalation, EXO 2 inhalation
- Where
- Russia
- Volunteers
- 90 people
- Sponsor
- Olga Tyumina
Acute Respiratory Distress Syndrome, COVID-19
Polyvalent Immunoglobulin in COVID-19 Related ARds
As of 30/03/2020, 715600 people have been infected with COVID-19 worldwide and 35500 people died, essentially due to respiratory distress syndrome (ARDS) complicated in 25% of the with acute renal failure.
- Trial name
- ICAR (NCT04350580)
- Testing
- Human immunoglobulin
- Where
- 42 sites in France
- Volunteers
- 146 people
- Sponsor
- Centre Hospitalier St Anne
Acute Lung Injury (ALI) Associated With COVID-19, Lung Inflammation Associated With COVID-19
TD-0903 for ALI Associated With COVID-19
This Phase 2 study will evaluate the efficacy, safety, pharmacodynamics and pharmacokinetics of inhaled TD-0903 compared with a matching placebo in combination with standard of care (SOC) in hospitalized patients with confirmed…
- Trial name
- NCT04402866
- Testing
- TD-0903
- Where
- 24 sites in United States, Brazil and 5 more
- Volunteers
- 235 people
- Sponsor
- Theravance Biopharma
COVID-19 Acute Respiratory Distress Syndrome
When to Apply to Which Patient in MSC?
Mesenchymal stem cell (MSC) therapy is among the promising treatments for acute respiratory distress syndrome (ARDS). Our study aimed to investigate the clinical efficacy of MSC treatment in COVID-19 patients, to determine when…
- Trial name
- MSC (NCT05240430)
- Testing
- Mesenchymal Stem Cell Antigen-1, Human
- Where
- Turkey (Türkiye)
- Volunteers
- 1 people
- Sponsor
- Trabzon Kanuni Education and Research Hospital
COVID-19, Coronavirus Infection
St. Jude Tracking of Viral and Host Factors Associated With COVID-19
This is a prospective adaptive cohort study of St. Jude employees to determine the rate of SARS-CoV-2 infections that are asymptomatic and to evaluate immunological responses to SARS-CoV-2 infection.
- Conditions
- COVID-19, Coronavirus Infection, Coronavirus, SARS-CoV-2
- Trial name
- NCT04362995
- Where
- United States
- Volunteers
- 1,316 people
- Sponsor
- St. Jude Children's Research Hospital
Sars-CoV-2 Infection, Lung Fibrosis
Low-field Magnetic Resonance Imaging of Pediatric COVID-19
SARS-CoV-2 (Severe acute respiratory syndrome coronavirus type 2) is a new coronavirus and identified causative agent of COVID-19 disease. They predominantly cause mild colds but can sometimes cause severe pneumonia.
- Conditions
- Sars-CoV-2 Infection, Lung Fibrosis, Covid19
- Trial name
- DECRYPT (NCT04990531)
- Testing
- Low-field magnetic resonance imaging, Blood sample
- Where
- Germany
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- University of Erlangen-Nürnberg Medical School
Covid19, SARS-Associated Coronavirus
Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild Symptoms
The COVID-19 pandemic has been characterized by high morbidity and mortality, especially in certain subgroups of patients. To date, no treatment has been shown to be effective in patients with early-onset disease and mild…
- Trial name
- NCT04727424
- Testing
- Spirulin Platensis, Budesonide Powder, Fluoxetine 20 MG
- Where
- 12 sites in Brazil
- Volunteers
- 7,819 people
- Sponsor
- Cardresearch
Covid19
Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)
This study looks at the safety and effectiveness of Aviptadil in treating COVID-19 in people who have been hospitalized with the infection and who have acute respiratory failure.
- Trial name
- NCT06729606
- Testing
- Aviptadil, Corticosteroid
- Where
- 40 sites in United States
- Volunteers
- 471 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID, Sars-CoV2
Prospective Registry of Corona Virus Disease 2019 (Covid-19) Patients With Neuromuscular Involvement
Prospective registry for multimodal assessment of neuromuscular pathology associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, enrolling consecutive patients with corona virus disease 2019…
- Conditions
- COVID, Sars-CoV2, Corona Virus Infection, Myositis
- Trial name
- NCT04367350
- Testing
- laboratory biomarkers, muscle ultrasound
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- University Hospital Tuebingen
Coronavirus, Respiratory Failure
Angiotensin-(1,7) Treatment in COVID-19: the ATCO Trial
Background: A novel Coronavirus (SARS-CoV-2) described in late 2019 in Wuhan, China, has led to a pandemic and to a specific coronavirus-related disease (COVID-19), which is mainly characterized by a respiratory involvement.
- Conditions
- Coronavirus, Respiratory Failure, Coronavirus Sars-Associated as Cause of Disease Classified Elsewhere, SARS-CoV-2
- Trial name
- ATCO (NCT04332666)
- Testing
- Angiotensin 1-7
- Volunteers
- 60 people
- Sponsor
- Erasme University Hospital
Covid19
Prolonged Symptoms and Reasons for Consultation in Town Medicine Associated With COVID-19 Infection in the Hauts de France Region
Several publications document the occurrence of prolonged or late-onset symptoms beyond 3 weeks after the first clinical manifestations of SARS-COV2 infection.
- Trial name
- COCO_Vi_LATE (NCT04817293)
- Testing
- Questionnaire, medical consultation
- Where
- France
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Tourcoing Hospital
Covid19
ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19
This study looks at the safety and effectiveness of different drugs in treating COVID-19 in people who have been hospitalized with the infection and who have acute respiratory failure.
- Trial name
- TESICO (NCT04843761)
- Testing
- Remdesivir, Aviptadil, Corticosteroid
- Where
- 40 sites in United States
- Volunteers
- 473 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID, SARS-CoV 2
Oxygen-Ozone as Adjuvant Treatment in Early Control of COVID-19 Progression and Modulation of the Gut Microbial Flora
Italy was the first European country affected by a severe outbreak of the Severe Acute Respiratory Syndrome - CoronaVirus-2 (SARS-CoV-2) epidemic emerged from Wuhan region (China), with a high morbidity and mortality associated…
- Conditions
- COVID, SARS-CoV 2, Pneumonia, Viral, Coronavirus Infection
- Trial name
- PROBIOZOVID (NCT04366089)
- Testing
- Oxygen-ozone therapy, probiotic supplementation and Standard of care, SivoMixx (200 billion), Azithromycin
- Where
- Italy
- Volunteers
- 152 people
- Sponsor
- Roberto Poscia MD, PhD
COVID-19
Study to Evaluate the Efficacy and Safety of Maraviroc in SARS-CoV-2 Infection (COVID-19).
This is a bicentric, phase 2, randomized, open-label study to evaluate the efficacy and safety of maraviroc associated with standard treatment in hospitalized patients with pulmonary SARS-CoV-2 infection (COVID-19).
- Trial name
- MARACOVID (NCT04441385)
- Testing
- Maraviroc 300 mg, Standard care therapy
- Where
- 2 sites in Spain
- Volunteers
- 60 people
- Sponsor
- Hospital Universitario Infanta Leonor
Severe COVID-19
COVID-19 and VA-LRTI: Second Versus First Wave of the Pandemic
Multicenter observational retrospective cohort study aiming at comparing the incidence of ventilator-associated lower respiratory tract infections between COVID-19 patients from the first and the second wave of the pandemic.
- Trial name
- CoVAPid2 (NCT05256511)
- Where
- France
- Sponsor
- University Hospital, Lille